Literature DB >> 19446813

Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis?

Joanna Jagielska1, Gustavo Salguero, Bernhard Schieffer, Udo Bavendiek.   

Abstract

Pro-inflammatory processes initiated in the endothelium represent a crucial step in the pathogenesis of inflammatory cardiovascular disease, such as atherosclerosis. Recent observations pointed to potential anti-inflammatory properties of the cardiac glycoside digitoxin. Therefore, the present study investigated potential anti-inflammatory and vasoprotective properties of digitoxin as well as the underlying signaling pathways affected in endothelial cells (EC). Digitoxin, employing therapeutical concentrations used in patients (3-30nM), potently inhibited the IL-1beta-induced expression of MCP-1 and VCAM-1 in EC and the capacity of corresponding cell culture supernatants on monocyte migration as well as monocyte adhesion to endothelial monolayers, respectively. Furthermore, digitoxin prevented the IL-1beta-induced activation of p44/42-MAPK and NF-kappaB without affecting activation of JNK and p38-MAPK. Inhibition of NF-kappaB signaling but not p44/42-MAPK mimicked the observed inhibitory effects of digitoxin on MCP-1 expression and monocyte migration. Moreover, digitoxin inhibited NF-kappaB signaling at the level of TAK-1/IKK. Additionally, digitoxin prevented TNF-alpha-induced apoptosis in EC accompanied by activation of Akt. Blockade of PI-3-kinase, activator of Akt, prevented the anti-apoptotic properties of digitoxin and impaired its inhibitory action on NF-kappaB signaling and MCP-1 expression. Finally, digitoxin activated endothelial NO-synthase, which was blocked by inhibition of PI-3-kinase, Ca(2+)/Calmodulin-dependent-proteinkinase-II and chelation of intracellular calcium. Digitoxin elicits anti-inflammatory and vasoprotective properties by blocking NF-kappaB and activating PI-3-kinase/Akt signaling as well as Ca(2+)/Calmodulin-dependent-proteinkinase-II in EC. These observations indicate a potential therapeutical application of digitoxin in the treatment of cardiovascular diseases, such as atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446813     DOI: 10.1016/j.atherosclerosis.2009.03.019

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Real-time analysis of the effects of toxic, therapeutic and sub-therapeutic concentrations of digitoxin on lung cancer cells.

Authors:  R Eldawud; T A Stueckle; S Manivannan; H Elbaz; M Chen; Y Rojanasakul; C Z Dinu
Journal:  Biosens Bioelectron       Date:  2014-03-26       Impact factor: 10.618

2.  MAP-Kinase Activated Protein Kinase 2 Links Endothelial Activation and Monocyte/macrophage Recruitment in Arteriogenesis.

Authors:  Anne Limbourg; Johann von Felden; Kumaravelu Jagavelu; Kashyap Krishnasamy; L Christian Napp; Piyushkumar R Kapopara; Matthias Gaestel; Bernhard Schieffer; Johann Bauersachs; Florian P Limbourg; Udo Bavendiek
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

3.  Digoxin inhibits PDGF-BB-induced VSMC proliferation and migration through an increase in ILK signaling and attenuates neointima formation following carotid injury.

Authors:  Gaoliang Yan; Qingjie Wang; Shengda Hu; Dong Wang; Yong Qiao; Genshan Ma; Chengchun Tang; Yuchun Gu
Journal:  Int J Mol Med       Date:  2015-08-21       Impact factor: 4.101

Review 4.  Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism.

Authors:  Srabani Pal; Ashish Bhattacharjee; Asif Ali; Narayan C Mandal; Subhash C Mandal; Mahadeb Pal
Journal:  J Inflamm (Lond)       Date:  2014-08-09       Impact factor: 4.981

5.  Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.

Authors:  Udo Bavendiek; Dominik Berliner; Lukas Aguirre Dávila; Johannes Schwab; Lars Maier; Sebastian A Philipp; Andreas Rieth; Ralf Westenfeld; Christopher Piorkowski; Kristina Weber; Anja Hänselmann; Maximiliane Oldhafer; Sven Schallhorn; Heiko von der Leyen; Christoph Schröder; Christian Veltmann; Stefan Störk; Michael Böhm; Armin Koch; Johann Bauersachs
Journal:  Eur J Heart Fail       Date:  2019-03-20       Impact factor: 15.534

6.  In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis.

Authors:  Camila S Freitas; Daniela P Lage; João A Oliveira-da-Silva; Rafaella R Costa; Débora V C Mendonça; Vívian T Martins; Thiago A R Reis; Luciana M R Antinarelli; Amanda S Machado; Grasiele S V Tavares; Fernanda F Ramos; Rory C F Brito; Fernanda Ludolf; Miguel A Chávez-Fumagalli; Bruno M Roatt; Gabriela S Ramos; Jennifer Munkert; Flaviano M Ottoni; Priscilla R V Campana; Mariana C Duarte; Denise U Gonçalves; Elaine S Coimbra; Fernão C Braga; Rodrigo M Pádua; Eduardo A F Coelho
Journal:  Parasite       Date:  2021-04-14       Impact factor: 3.000

7.  Digitoxin and its analogs as novel cancer therapeutics.

Authors:  Hosam A Elbaz; Todd A Stueckle; William Tse; Yon Rojanasakul; Cerasela Zoica Dinu
Journal:  Exp Hematol Oncol       Date:  2012-04-05

8.  Inhibition of hypoxia inducible factor-1α attenuates abdominal aortic aneurysm progression through the down-regulation of matrix metalloproteinases.

Authors:  Shih-Hung Tsai; Po-Hsun Huang; Yu-Juei Hsu; Yi-Jen Peng; Chien-Hsing Lee; Jen-Chun Wang; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Sci Rep       Date:  2016-07-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.